(Q49031219)

17 February 2018

title

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. (English)

1 reference

17 February 2018

0 references

0 references

S Vermeire

6

0 references

author name string

M De Vos

1

1 reference

17 February 2018

O Dewit

2

1 reference

17 February 2018

G D'Haens

3

1 reference

17 February 2018

F Baert

4

1 reference

17 February 2018

F Fontaine

5

1 reference

17 February 2018

D Franchimont

7

1 reference

17 February 2018

T Moreels

8

1 reference

17 February 2018

D Staessen

9

1 reference

17 February 2018

L Terriere

10

1 reference

17 February 2018

B Vander Cruyssen

11

1 reference

17 February 2018

E Louis

12

1 reference

17 February 2018

behalf of BIRD

13

1 reference

17 February 2018

publication date

11 December 2011

1 reference

17 February 2018

Journal of Crohn's and Colitis

published in

1 reference

17 February 2018

volume

6

1 reference

17 February 2018

issue

5

1 reference

17 February 2018

page(s)

557-562

1 reference

17 February 2018

Infliximab for induction and maintenance therapy for ulcerative colitis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

Predictors of early response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2011.11.002

10.1016/J.CROHNS.2011.11.002

21 January 2018

Identifiers

DOI

1 reference

17 February 2018

1 reference

17 February 2018